NCT05308940View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of TB001 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 10, 2022

Primary Completion Date

August 23, 2022

Study Completion Date

August 23, 2022

Conditions
Healthy
Interventions
DRUG

TB001

once-daily subcutaneous injection, on Day 1 in SAD stage

DRUG

TB001

once-daily subcutaneous injection, on Days 1-7 in MAD stage

DRUG

Placebo

once-daily subcutaneous injection, on Day 1 in SAD stage

DRUG

Placebo

once-daily subcutaneous injection, on Days 1-7 in MAD stage

Trial Locations (1)

518122

Shenzhen Turier Biotech Co., Ltd., Shenzhen

All Listed Sponsors
lead

Shenzhen Turier Biotech Co., Ltd

OTHER